particular improving bladder function in patients suffering from, is recovering from and/or has suffered from a neurological disorder. Without being bound to a theory, it is believed that the mixture of uridine and n-3 PUFAs could improve the neurological function of the bladder and the connection between bladder and brain by supporting the regenerative processes which occur e.g. after spinal cord injury. The example shows that the composition according to the invention indeed leads to significantly improved bladder function. Bladder function is restored significantly faster upon administration of the composition according to the invention.

In one aspect of the disclosure, there is provided the use of uridine and/or an equivalent thereof selected from the group consisting of deoxyuridine, uridine phosphates, nucleobase uracil and/or acylated uridine deriates and/or esters; and n-3 polyunsaturated fatty acid (PUFA) for the manufacture of a medicament for restoring or improving impaired bladder function in a subject. The present disclosure thus concerns a method for restoring or improving bladder function in a subject, comprising administering to the subject a composition comprising (i) uridine and/or an equivalent thereof and (ii) n-3 PUFA.

In another aspect, the disclosure concerns a composition for use in restoring or improving bladder function in a subject, comprising (i) uridine and/or an equivalent thereof and (ii) n-3 PUFA. The disclosure also concerns a combination of (i) uridine and/or an equivalent thereof and (ii) n-3 PUFA for use in restoring or improving bladder function in a subject.

In a first preferred embodiment, the uridine and/or equivalent thereof as mentioned in the context of the disclosure is uridine monophosphate. In a second preferred embodiment, the n-3 PUFA is selected from EPA and/or DHA, preferably at least DHA. In a third preferred embodiment, the composition further comprises one or more of choline, B vitamin(s), said B vitamin(s) preferably comprising or being at least folic acid, more preferably at least folic acid and vitamin B6, and antioxidants. In a fourth preferred embodiment, the composition comprises at least choline. In a most preferred embodiment, the composition further comprises choline, folic acid, vitamin B6,

antioxidants and phospholipids. In a fifth preferred embodiment, the subject is a patient who is suffering from, is recovering from and/or has suffered from a neurological disorder, preferably from spinal cord injury. In a sixth preferred embodiment, the composition comprises per 100 mL: (i) 400 – 800 mg UMP; (ii) n-3 PUFAs comprising

Claims

1. Use of (i) uridine and/or an equivalent thereof selected from the group consisting of deoxyuridine, uridine phosphates, nucleobase uracil and/or acylated uridine derivatives and/or esters; and (ii) n-3 polyunsaturated fatty acid (PUFA) for the manufacture of a medicament for restoring or improving impaired bladder function in a subject.
2. Use according to claim 1, wherein the subject is a patient who is suffering , is recovering and/or has suffered from a neurological disorder, preferably from spinal cord injury.
3. Use according to claim 1 or 2, wherein the n-3 PUFA is selected from eicosapentaenic acid (EPA) and/or docosahexaenoic acid (DHA).
4. Use according to any one of the preceding claims, wherein 500 – 5000 mg DHA is to be administered per day.
5. Use according to any one of the preceding claims, wherein the medicament further comprises choline, and preferably further comprises B vitamin(s).
6. Use according to any one of the preceding claims, wherein the medicament further comprises phospholipids, choline, B vitamin(s) and antioxidants.
7. Use according to claim 5 or 6, wherein the medicament comprises choline, vitamin B6 and folic acid.
8. Use according to any one of the preceding claims, wherein the uridine and/or equivalent thereof is uridine monophosphate (UMP).
9. Use according to any one of the preceding claims, wherein the medicament comprises per 125 mL or per daily dosage:
   (i) 400 – 800 mg UMP;
   (ii) n-3 PUFAs comprising (a) 100 – 500 mg EPA and (b) 900 – 1500 mg DHA;
   (iii) 50 – 600 mg phospholipids;
   (iv) 200 – 600 mg choline;
   (v) B vitamins comprising (a) 1 – 5 µg vitamin B12, (b) 0.5 – 3 mg vitamin B6 and (c) 200 – 600 µg folic acid; and
   (vi) antioxidants comprising (a) 20 – 60 mg vitamin E (alpha-TE), (b) 60 – 100 mg vitamin C, and (c) 40 – 80 µg selenium.
10. Use according to any one of the preceding claims, wherein the medicament is a liquid or a solid, which is reconstitutable with a liquid.

11. Use according to any one of the preceding claims, wherein said medicament is to be administered to said subject suffering from impaired bladder function.

12. Use according to any one of the preceding claims, wherein the neurological disorder is selected from brain injury, spinal cord injury, sacral cord injury or peripheral nerve injury.

13. Use according to any one of the preceding claims, wherein the neurological disorder is selected from paraplegia, quadriplegia, Multiple Sclerosis and myelomeningocele, Parkinson's disease, stroke, traumatic spinal cord injury or traumatic brain injury.